Tempus AI (NASDAQ:TEM) shares rose 2.7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.
Piper Sandler upgraded Tempus AI to “Overweight” from “Neutral” and increased its price target to $76 from $56.
The brokerage cited three factors in its assessment: Personalis’ tumor-informed minimal residual disease platform, results from the INTerpath-001 study and FDA approval of Tempus AI’s tumor-only xT genomic test.
The rating and price target represent Piper Sandler’s assessment and do not indicate future share-price performance.
Canaccord maintains Buy rating after S-4 filing
Canaccord Genuity reiterated its “Buy” rating and $80 price target following Tempus AI’s S-4 filing on August 31, which provided additional information about the process leading to the proposed Personalis acquisition.
According to the filing information supplied, the Personalis sale process began in May 2024 and involved interest from several strategic parties.
One potential bidder was described as a direct competitor whose proposal raised significant antitrust concerns. The eventual regulatory treatment and completion of the Tempus AI transaction remain subject to the applicable conditions and processes.
Canaccord’s $80 target represents the brokerage’s valuation estimate rather than an indication of where Tempus AI shares will trade.
Tempus AI raised 2026 revenue guidance
The analyst actions follow Tempus AI’s second-quarter results, when the company reported a move to profitability and increased its full-year 2026 revenue guidance to approximately $1.6 billion, according to the supplied information.
The pending Personalis acquisition would add the company’s tumor-informed MRD capabilities to Tempus AI’s existing operations if the transaction is completed as planned.
The financial and strategic impact of the acquisition will depend on its completion and subsequent integration.
Shares advance as broader U.S. markets decline
Tempus AI’s pre-market increase came as major U.S. equity indices were indicated lower. The S&P 500 and Dow Jones each declined approximately 0.5%, while the Nasdaq fell nearly 1.0%.
Tempus AI shares were trading above their 52-week low of $40.77 but remained below their 52-week high of $104.32.
Tuesday’s 2.7% increase coincided with Piper Sandler’s upgrade, Canaccord’s reiterated rating and additional information from the S-4 filing. While these developments provide context for the move, the supplied information does not establish the extent to which any individual factor caused the pre-market gain.
Tempus AI stock price
